About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring and commercializing innovative therapeutics for men's health issues, including erectile dysfunction, Peyronie's disease, hormone health and substance use disorders.
Petros Pharmaceuticals, Inc. Launches Two Self-Selection Studies For Erectile Dysfunction Drug Stendra® (Avanafil): Results from these studies will be part of a broader data package the company plans to submit to the U.S. Food and Drug Administration (FDA) to potentially obtain over-the-counterdrug status for STENDRA® (avanafil).
Petros Pharmaceuticals Is Expanding Its Program For A Novel, Non-Invasive Treatment For Peyronie's Disease: In an effort to expand its portfolio to other underserved segments, Petros Pharmaceuticals recently entered into a definitive global exclusive license agreement for a novel and patented topical formulation candidate for the treatment of Peyronie's disease (PD), which is currently in early clinical testing. If approved, this would be the first and only clinically proven topical, non-invasive treatment for acute PD, a breakthrough achievement in men's health.
Petros Pharmaceuticals' Foundation: Petros Pharmaceuticals, formerly known as Metuchen Pharma, was founded in 2020 and is headquartered in the United States.
Petros Pharmaceuticals' Vision: Petros Pharmaceuticals' vision is to provide optimised men's health solutions that address the full spectrum of conditions that are specific to men, whether they focus on the male anatomy or pose an increased risk to men.
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Petros Pharmaceuticals
|Address||StreetAddress: 1185 Avenue of the Americas Fl 3, AddressLocality: New York City, AddressRegion: New York, PostalCode: 10036, AddressCountry: United States|
|Number Of Employees||24|
|Ticker Symbol||NASDAQ: PTPI|
New York City, US
24 Sep 2023
Petros Pharma (Pharmaceutical company)
Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announces the expansion of the FDA labeling for its oral erectile dysfunction (ED) drug, STENDRA® (avanafil), marketed by its subsidiary, Metuchen Pharmaceuticals.finance.yahoo.com/quote/PTPI/#:~:text=Undergone%20Radical%20Prostatectomy-,Petros%20Pharmaceuticals%2C%20Inc.,by%20its%20subsidiary%2C%20Metuchen%20Pharmaceuticals.
Stock price : PTPI (NASDAQ) $1.51 -0.08 (-5.03%)Sep 22, 4:00 PM EDT - Disclaimer
Headquarters : United States
Founded : 2020